Cargando…
An Unusual Case of Lorlatinib-Induced Pneumonitis: A Case Report
The discovery of tyrosine kinase oncogenic driver mutations, including anaplastic lymphoma kinase (ALK), has changed the face of non-small cell lung cancer (NSCLC) treatment. Whilst the development of tyrosine kinase inhibitors has improved survival, with their increasing use, it is important to be...
Autores principales: | Harrison, Philippa Kate, Boland, Helen E, Aherne, Noel J, Palmieri, David J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958573/ https://www.ncbi.nlm.nih.gov/pubmed/35431862 http://dx.doi.org/10.1159/000520158 |
Ejemplares similares
-
Lorlatinib‐induced visual and auditory hallucinations: A case report
por: Hakamata, Jun, et al.
Publicado: (2021) -
Flecainide-induced pneumonitis: a case report
por: Moureau, Gauthier, et al.
Publicado: (2022) -
Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series
por: Myall, Nathaniel J., et al.
Publicado: (2021) -
Immunotherapy-induced pneumonitis: cases report
por: Helber, Henrique Alkalay, et al.
Publicado: (2018) -
Tozinameran: Vaccine-induced pneumonitis: case report
Publicado: (2022)